News coverage about Haemonetics (NYSE:HAE) has been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Haemonetics earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news articles about the medical instruments supplier an impact score of 46.2080722776484 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of HAE opened at $112.02 on Friday. Haemonetics has a 52-week low of $41.54 and a 52-week high of $113.61. The company has a market capitalization of $5.79 billion, a price-to-earnings ratio of 59.90, a price-to-earnings-growth ratio of 4.61 and a beta of 1.01. The company has a current ratio of 2.84, a quick ratio of 1.94 and a debt-to-equity ratio of 0.49.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Tuesday, August 7th. The medical instruments supplier reported $0.59 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.42 by $0.17. Haemonetics had a return on equity of 15.00% and a net margin of 2.45%. The business had revenue of $229.35 million during the quarter, compared to the consensus estimate of $219.52 million. sell-side analysts expect that Haemonetics will post 2.28 earnings per share for the current fiscal year.

Several equities analysts recently commented on HAE shares. Jefferies Financial Group boosted their price target on Haemonetics from $95.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, June 14th. Morgan Stanley upped their target price on Haemonetics from $100.00 to $120.00 and gave the company an “overweight” rating in a research report on Wednesday, August 8th. Zacks Investment Research raised Haemonetics from a “hold” rating to a “buy” rating and set a $105.00 target price on the stock in a research report on Tuesday, June 12th. TheStreet lowered Haemonetics from a “b” rating to a “c+” rating in a research report on Monday, August 20th. Finally, Barrington Research upped their target price on Haemonetics from $90.00 to $118.00 and gave the company an “outperform” rating in a research report on Thursday, August 9th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Haemonetics has a consensus rating of “Buy” and an average target price of $98.33.

In other news, CEO Christopher Simon sold 3,595 shares of the business’s stock in a transaction that occurred on Friday, June 29th. The stock was sold at an average price of $40.39, for a total value of $145,202.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO William P. Mr. Burke sold 6,687 shares of the business’s stock in a transaction that occurred on Monday, June 25th. The shares were sold at an average price of $92.17, for a total value of $616,340.79. The disclosure for this sale can be found here. Insiders sold a total of 16,880 shares of company stock valued at $1,284,307 over the last quarter. Company insiders own 1.04% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

See Also: Google Finance Portfolio Workaround

Insider Buying and Selling by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.